#1 Clinical Trials Search in Europe

Paclitaxel Albumin-Bound

This article discusses several clinical trials investigating the use of paclitaxel albumin-bound (also known as nab-paclitaxel or Abraxane) in treating various types of cancer, particularly breast cancer and lung cancer. These trials aim to evaluate the efficacy and safety of paclitaxel albumin-bound when combined with other treatments like immunotherapy and targeted therapies.

Table of Contents

What is PACLITAXEL ALBUMIN-BOUND?

PACLITAXEL ALBUMIN-BOUND, also known as nab-paclitaxel, is an anticancer medication used to treat various types of cancer. It’s a form of paclitaxel, a chemotherapy drug, that is bound to a protein called albumin. This medication is sold under the brand name Abraxane[1].

How it Works

PACLITAXEL ALBUMIN-BOUND works by interfering with the growth and spread of cancer cells in your body. The albumin binding allows the medication to be delivered more effectively to cancer cells compared to standard paclitaxel. This means it can potentially be more effective while causing fewer side effects[1].

Medical Uses

PACLITAXEL ALBUMIN-BOUND is used to treat several types of cancer, including:

  • Metastatic breast cancer: Particularly triple-negative breast cancer (TNBC), which is a type of breast cancer that doesn’t respond to hormonal therapy or medicines that target HER2 protein[2].
  • Non-small cell lung cancer (NSCLC): Both squamous and non-squamous types[3].
  • Pancreatic cancer: Specifically, metastatic adenocarcinoma of the pancreas[4].

How it’s Administered

PACLITAXEL ALBUMIN-BOUND is typically given as an intravenous (IV) infusion. The dosage and frequency can vary depending on the type of cancer being treated and other factors. Common dosages include:

  • 100 mg/m² given weekly[1]
  • 260 mg/m² given every three weeks[5]

Your healthcare provider will determine the appropriate dosage and schedule for your specific situation.

Potential Side Effects

Like all medications, PACLITAXEL ALBUMIN-BOUND can cause side effects. Some common side effects include:

  • Fatigue
  • Hair loss
  • Nausea and vomiting
  • Diarrhea or constipation
  • Decreased blood cell counts, which can increase risk of infection or bleeding
  • Numbness or tingling in hands and feet (peripheral neuropathy)

It’s important to discuss any side effects you experience with your healthcare provider[3].

Precautions and Considerations

Before starting treatment with PACLITAXEL ALBUMIN-BOUND, inform your doctor about:

  • Any allergies, especially to paclitaxel or human albumin
  • All medications you’re taking, including over-the-counter drugs and supplements
  • Any liver or kidney problems
  • If you’re pregnant, planning to become pregnant, or breastfeeding

PACLITAXEL ALBUMIN-BOUND can interact with other medications and may not be suitable for everyone[6].

Ongoing Research

Researchers continue to study PACLITAXEL ALBUMIN-BOUND to understand its full potential in cancer treatment. Current clinical trials are exploring its use:

  • In combination with immunotherapy drugs for treating metastatic triple-negative breast cancer[2].
  • As part of combination therapies for advanced pancreatic cancer[4].
  • In various combinations for treating non-small cell lung cancer[6].

These ongoing studies aim to improve treatment outcomes and explore new ways to use this medication effectively in cancer therapy.

Trial Focus Cancer Type Combination Treatments Key Endpoints
Imaging with 89Zr-atezolizumab Metastatic triple-negative breast cancer Atezolizumab, carboplatin PD-L1 status agreement, therapy-predictive value
Preoperative treatment Borderline resectable pancreatic cancer mFOLFIRINOX or gemcitabine, stereotactic body radiation therapy R0 resection rate, disease-free survival
Subcutaneous vs. intravenous pembrolizumab Metastatic non-small cell lung cancer Pembrolizumab, chemotherapy Pharmacokinetics, safety, efficacy
Tiragolumab and atezolizumab Early and metastatic triple-negative breast cancer Tiragolumab, atezolizumab, chemotherapy Efficacy, safety, biomarker analysis
Inavolisib and Phesgo HER2-positive, PIK3CA-mutated breast cancer Inavolisib, Phesgo (pertuzumab, trastuzumab, hyaluronidase) Progression-free survival, overall survival
RO7247669 vs. pembrolizumab PD-L1 positive triple-negative breast cancer RO7247669 or pembrolizumab Progression-free survival, objective response rate

FAQ

  • What is paclitaxel albumin-bound? Paclitaxel albumin-bound, also known as nab-paclitaxel or Abraxane, is a chemotherapy drug used to treat various types of cancer. It is a form of paclitaxel that is bound to albumin protein particles, which helps deliver the medication more effectively to cancer cells.
  • What types of cancer are being studied with paclitaxel albumin-bound in these trials? The clinical trials mentioned in this article are studying paclitaxel albumin-bound in treating various types of cancer, including metastatic triple-negative breast cancer, HER2-positive breast cancer, non-small cell lung cancer, and pancreatic cancer.
  • How is paclitaxel albumin-bound administered in these trials? In these trials, paclitaxel albumin-bound is typically administered intravenously (through an IV) at doses ranging from 100 to 260 mg/m2, depending on the specific trial and treatment regimen.
  • What other treatments are being combined with paclitaxel albumin-bound in these studies? Paclitaxel albumin-bound is being studied in combination with various other treatments, including immunotherapy drugs (such as atezolizumab, pembrolizumab, and tiragolumab), targeted therapies (like inavolisib), and other chemotherapy agents (such as carboplatin and gemcitabine).
  • What are the main goals of these clinical trials? The main goals of these clinical trials are to evaluate the efficacy, safety, and tolerability of paclitaxel albumin-bound in combination with other treatments. Researchers are looking at outcomes such as progression-free survival, overall survival, objective response rates, and the incidence of adverse events.

Ongoing Clinical Trials on Paclitaxel Albumin-Bound

  • A Study of BMS-986504 Combined with Nab-Paclitaxel and Gemcitabine for Patients with Untreated Metastatic Pancreatic Cancer with MTAP Gene Deletion

    Recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +9

  • Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium France Germany Hungary Italy +3

  • Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

    Recruiting

    1 1 1 1
    Investigated drugs:
    France Germany Italy The Netherlands Spain

  • Study of patritumab deruxtecan versus drug combination in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Greece Hungary Italy Poland +1

  • Maintenance Therapy Study of Inavolisib with Pertuzumab and Trastuzumab in Patients with HER2‑Positive, PIK3CA‑Mutated Locally Advanced or Metastatic Breast Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    Belgium Finland France Germany Italy Poland +1

  • A study of mRNA-4157 and a drug combination for patients with stage IV non-small cell lung cancer

    Recruiting

    1 1
    Investigated drugs:
    France Italy Poland Spain

  • Study of BNT327 and a drug combination for patients with untreated metastatic or locally recurrent triple-negative breast cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia France Germany Italy The Netherlands +2

  • Study comparing datopotamab deruxtecan with or without durvalumab to chemotherapy with pembrolizumab for patients with triple-negative breast cancer

    Recruiting

    1 1 1 1
    Investigated drugs:
    France Italy Poland Spain

  • A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Denmark France +9

  • Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria France Germany Greece Italy Poland +4

Glossary

  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Triple-negative breast cancer (TNBC): A type of breast cancer that tests negative for estrogen receptors, progesterone receptors, and excess HER2 protein.
  • HER2-positive: A type of breast cancer that has high levels of a protein called human epidermal growth factor receptor 2 (HER2).
  • Non-small cell lung cancer (NSCLC): A group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Objective response rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Adverse events: Any unfavorable and unintended sign, symptom, or disease associated with the use of a medical treatment or procedure.
  • Immunotherapy: A type of cancer treatment that helps the immune system fight cancer.
  • Targeted therapy: A type of cancer treatment that targets specific genes, proteins, or other molecules that contribute to cancer growth and survival.
  • PD-L1: A protein found on some cancer cells that can help them evade the immune system.
  • PIK3CA mutation: A genetic alteration found in some cancers that can affect cell growth and survival.

References

  1. http://clinicaltrials.eu/trial/study-on-imaging-with-89zr-atezolizumab-to-monitor-immune-responses-in-patients-with-metastatic-triple-negative-breast-cancer-using-atezolizumab-and-drug-combination/
  2. http://clinicaltrials.eu/trial/study-on-tiragolumab-atezolizumab-and-chemotherapy-for-patients-with-early-and-metastatic-triple-negative-breast-cancer/
  3. http://clinicaltrials.eu/trial/study-comparing-subcutaneous-pembrolizumab-with-hyaluronidase-to-intravenous-pembrolizumab-and-chemotherapy-for-first-line-treatment-of-metastatic-non-small-cell-lung-cancer/
  4. http://clinicaltrials.eu/trial/study-on-preoperative-treatment-with-mfolfirinox-or-gemcitabine-paclitaxel-for-patients-with-borderline-resectable-pancreatic-cancer/
  5. http://clinicaltrials.eu/trial/study-on-inavolisib-and-phesgo-for-patients-with-her2-positive-pik3ca-mutated-advanced-breast-cancer/
  6. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-retifanlimab-with-chemotherapy-for-patients-with-metastatic-non-small-cell-lung-cancer/